RNS Number:3568R
Medical Marketing Int'l Group PLC
28 October 2003

FOR IMMEDIATE RELEASE                                            28 OCTOBER 2003

           MMI TO BE GRANTED EUROPEAN PATENT FOR ANTI CANCER THERAPY

Medical Marketing International Group plc (MMI) the Cambridge, UK-based
technology management company listed on the London Stock Exchange (LSE:MMG)
announces that it has been formally notified by the European Patent Office that
the patent for the ruthenium anti-cancer therapy being developed by MMI's
wholly-owned subsidiary Oncosense, will be granted.

MMI announced on 18th September 2003 that the Oncosense ruthenium compounds had
the potential to be a whole new class of cancer therapy showing potency at least
as good as the market-leading therapies carboplatin and cisplatin and with the
potential for reduced toxicity, a novel mechanism of action and non-cross
resistance. Additionally data showed that the ruthenium compounds each have
their own spectrum of activity, with individual compounds showing differential
activity against individual cell lines including non-small cell lung cancer,
breast cancer and melanoma.

David Best, Chairman of MMI, commenting on today's announcement said:  "The
early notification of intention to grant the European ruthenium patent is great
news for MMI and Oncosense. It will help strengthen the Company's commercial
position as well as enabling us to potentially develop a whole range of
ruthenium anti-cancer therapies."


For further information, please contact:

David Best - Executive Chairman
MMI Group                                               Tel: +44 (0)1223 477677
www.mmigroup.co.uk

Lisa Baderoon
Buchanan Communications                                 Tel: +44 (0)20 7466 5000
lisab@buchanan.uk.com




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCFELFMWSDSEES